Skip to main content

Generics

  • FDA outlines global food, drug, device safety strategy

    SILVER SPRING, Md. — Globalization has led to a rapid increase in the drugs and foods arriving on U.S. shores from abroad, a trend that has prompted U.S. regulators to transform their approach.

    The Food and Drug Administration released a report Monday detailing its strategies for what it called transforming from a domestic to a global public health agency.

  • Par buys rights to generic drug for GERD

    WOODCLIFF LAKE, N.J. — Par Pharmaceutical has bought rights to a generic drug for gastroesophageal reflux disease from Handa Pharmaceuticals, Par said.

    Handa, based in Fremont, Calif., sold rights to the regulatory approval application it filed with the Food and Drug Administration for dexlansoprazole capsules, a generic version of Takeda's Dexilant, in the 60-mg strength.

  • Watson launches authorized generic diabetes drug

    PARSIPPANY, N.J. — Watson Pharmaceuticals announced the launch of an authorized generic version of a drug used to lower blood glucose in patients with Type 2 diabetes.

  • Anda facilitates commerce

    PALM BEACH, Fla. — More than 250 executives joined Anda for its 5th Annual Supply Chain Symposium here Thursday and Friday.

    (For photos of the event, click here.)

  • Generics among fastest-growing industries this decade, report finds

    NEW YORK — According to the latest numbers, the country's economy is slowly growing, while unemployment has been slowly declining. But while growth has been somewhat less than stellar, 10 industries have outpaced the rest of the economy, including generic drugs.

  • GPhA signs on with IMS Health to address drug shortages

    WASHINGTON — A trade organization representing generic drug manufacturers announced Thursday its latest solution to the problem of drug shortages.

  • Watson seeks approval for generic Type 2 diabetes drug

    PARSIPPANY, N.J. — Generic drug maker Watson is challenging the patent protection on a drug used to treat Type 2 diabetes.

    Watson said Thursday that it had filed with the Food and Drug Administration for approval of a generic version of Depomed's Glumetza (metformin hydrochloride extended-release tablets) in the 1,000-mg strength.

  • Valeant buys product lines from Atlantis Pharma for $71 million

    MONTREAL — Valeant Pharmaceuticals International is acquiring "certain assets" of a drug maker based in Mexico.

    Valeant said Wednesday that it would buy gastric, analgesic and anti-inflammatory drugs from branded generics manufacturer Atlantis Pharma for $71 million. The products had sales of $26 million last year.

X
This ad will auto-close in 10 seconds